HER2 Overexpression as a Predictive Marker in a Randomized Trial Comparing Adjuvant Cyclophosphamide/Methotrexate/5-Fluorouracil with Epirubicin in Patients with Stage I/II Breast Cancer: Long-Term Results
Titel:
HER2 Overexpression as a Predictive Marker in a Randomized Trial Comparing Adjuvant Cyclophosphamide/Methotrexate/5-Fluorouracil with Epirubicin in Patients with Stage I/II Breast Cancer: Long-Term Results
Auteur:
Colozza, Mariantonietta Sidoni, Angelo Mosconi, Anna Maria Cavaliere, Antonio Bisagni, Giancarlo Gori, Stefania De Angelis, Verena Frassoldati, Antonio Cherubini, Roberta Bian, Alberto Rosa RodinĂ², Carmelina Mazzocchi, Bruno Mihailova, Zhasmina Bucciarelli, Emilio Tonato, Maurizio